{"filings":[{"id":724356,"accession_number":"0001104659-26-067649","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-05-28T21:21:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix increases at-market offering by $2.96M, total now up to $6.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 28, 2026, increasing shares issuable under Sales Agreement with Rodman & Renshaw by $2,956,000.","Prior sales under the agreement totaled approximately $3,445,000; combined maximum now $6,401,000.","Common stock (SNGX) offered on Nasdaq; legal opinion from Duane Morris LLP filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99009,"accession_number":"0001104659-26-049787","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix Phase 3 FLASH2 trial of HyBryte for CTCL halted for futility","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Data Monitoring Committee interim efficacy analysis recommended halt; HyBryte failed to show benefit at 18 weeks.","Company reports ~$5.9M cash; evaluating strategic options including M&A or advancing dusquetide for Behçet's Disease.","HyBryte previously showed statistically significant lesion reduction in Phase 3 FLASH study at 6 weeks, but not replicated in FLASH2.","Soligenix plans further data analysis to identify patient subsets; will discuss with FDA and EMA if warranted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114786,"accession_number":"0001104659-26-014267","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix provides pipeline update; FLASH 2 interim analysis in 2Q, cash through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["66 patients enrolled in confirmatory Phase 3 FLASH 2 trial for HyBryte in CTCL as of Feb 10; interim analysis expected 2Q 2026.","Blinded aggregate response rate in FLASH 2 remains higher than estimated rate used to design study, increasing confidence.","Investigator-initiated study: 75% of patients achieved treatment success, 3 complete responses with HyBryte at 18 weeks.","Cash ~$10.5M as of Sep 30, 2025, plus ~$500k from NJ NOL program; runway through 2026.","Positive Phase 2a results for SGX945 (Behçet’s) and SGX302 (psoriasis); Phase 2b design underway in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114785,"accession_number":"0001104659-26-006233","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix enters ATM equity facility with Rodman & Renshaw for up to $3.45M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $3,450,000 of common stock may be sold at market prices through Rodman & Renshaw as sales agent.","Commission of 3.0% of gross proceeds; facility expires December 15, 2026.","Company can sell shares at its discretion; no minimum obligation to sell.","Sales will be made via an at-the-market offering under existing shelf registration statement (File No. 333-274265)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131165,"accession_number":"0001104659-25-113645","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix regains Nasdaq minimum stockholders' equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Nov 18, 2025 confirming compliance with minimum $2.5M stockholders' equity requirement.","Stockholders' equity was $7,597,976 as of Sept 30, 2025, well above the $2.5M threshold.","Prior deficiency notice was received on Aug 15, 2025; now the matter is closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147743,"accession_number":"0001104659-25-094507","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soligenix closes $7.5M public offering; cash runway extended through 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$7.5M from sale of 5,555,560 units at $1.35/unit, each consisting of one share (or pre-funded warrant) and one warrant.","Warrants exercisable at $1.35 per share for five years from issuance; 1,162,064 existing warrants amended to same terms.","Cash runway now extends through end of 2026 to fund key clinical/commercial inflection points.","Net proceeds to fund R&D, commercialization, working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147742,"accession_number":"0001558370-25-011625","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Soligenix orphan drug designation for SGX945 in Behçet's Disease","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA orphan drug designation for dusquetide (SGX945) in Behçet's Disease based on Phase 2a results showing biological efficacy and safety.","Designation provides 7 years U.S. market exclusivity upon FDA approval, plus NDA fee waiver, tax credits, and clinical trial grants.","Behçet's Disease affects up to 18,000 in the U.S. and 1 million worldwide; current treatments have significant unmet need.","CEO notes Phase 2a study demonstrated clinically meaningful improvements in oral aphthous ulcers in Behçet's patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147741,"accession_number":"0001558370-25-011619","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix receives Nasdaq deficiency notice for stockholders' equity below $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $1,828,951 as of June 30, 2025, below Nasdaq's $2.5M minimum.","July 1 ATM sale raised ~$1.44M gross, but company still fails alternative listing standards.","Must submit compliance plan by Sept 29, 2025; if accepted, Nasdaq may extend up to 180 days.","Failure to regain compliance could lead to delisting; company may appeal to Nasdaq panel.","Common stock continues trading on Nasdaq Capital Market under SNGX pending plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147740,"accession_number":"0001104659-25-072708","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.","7 of 8 patients reported benefit; 1 patient's skin ulcer resolved; no treatment-related adverse events.","Improvement sustained at Week 8 (32%) despite stopping treatment at Week 4; Otezla continuous dosing had 41%.","Company plans reformulation for home subcutaneous injection and a placebo-controlled Phase 2 study.","Behçet's Disease affects ~18,000 in US; SGX945 well-tolerated with no GI side effects vs Otezla."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166429,"accession_number":"0001558370-25-008772","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Soligenix shareholders approve 2025 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan approved with 215,332 for, 91,937 against, 57,226 abstain; 1,168,832 broker non-votes.","Authorizes up to 6 million shares plus annual evergreen increase starting January 1, 2026.","Five directors elected: Schaber (330,950), Lapointe (332,492), Parks (331,054), Rubin (331,046), Zeldis (329,054).","Non-binding advisory vote on exec compensation passed: 303,633 for, 53,830 against.","Ratification of Cherry Bekaert LLP as auditor for FY2025 approved: 1,476,465 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183866,"accession_number":"0001558370-25-003987","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Soligenix amends bylaws to reduce stockholder meeting quorum to one-third from majority","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment effective March 25, 2025 reducing quorum from majority to one-third of voting power.","Company cited prior difficulties achieving quorum due to dispersed stockholder base and brokerage policy changes.","Amendment aims to avoid costly adjournments, increased proxy solicitation expenses, and management distraction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183865,"accession_number":"0001558370-25-000726","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Soligenix repays $10M Pontifax loan early, terminates Loan and Security Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid all outstanding obligations under the December 2020 Loan Agreement with Pontifax Medison Finance.","No prepayment penalty incurred; all related liens and security interests released.","Loan was originally $10 million, originated on December 15, 2020.","Shlomo Karako, Partner of the Lenders, praised positive collaboration and professionalism.","Company and subsidiaries terminated the Loan Agreement effective February 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200464,"accession_number":"0001558370-24-013257","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Soligenix amends loan deal with Pontifax; conversion price cut to $3.81/$4.23","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Conversion price reduced to $3.81 for first 501,648 shares issued after Oct 7, 2024, then $4.23 for subsequent shares.","Amendment allows Soligenix to satisfy remaining loan balance with stock instead of cash, extending cash runway.","Lenders agreed to lock-up in future offerings and capped aggregate stock ownership at 19.99% of outstanding shares.","All other terms of the December 2020 Loan and Security Agreement remain unchanged; effective October 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216495,"accession_number":"0001558370-24-012345","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix enters ATM equity sales agreement for up to $5.8M with AGP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with A.G.P./Alliance Global Partners allows sale of up to $5.8M in common stock at market prices from time to time.","Company will pay AGP a fixed commission rate of up to 3.0% of gross proceeds from sales under the agreement.","Sales may occur through The Nasdaq Capital Market until earliest of December 15, 2026, sale of all shares, or termination.","Shares issued under effective shelf registration statement declared Dec. 15, 2023; prospectus supplement filed Aug. 16, 2024.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216494,"accession_number":"0001558370-24-010107","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Soligenix regains Nasdaq compliance after reverse stock split, delisting threat resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 24, 2024 confirming regained compliance with Minimum Bid Price Rule.","Effected a 1-for-16 reverse stock split on June 5, 2024 to boost share price above $1.00.","Previously disclosed non-compliance as of June 23, 2023; hearings panel closed matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216493,"accession_number":"0001558370-24-009712","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Soligenix induces warrant exercise for up to $4.2M, issues new warrants at 150% coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to 703,125 existing warrants exercised at $6.00/share; gross proceeds up to ~$4.2M.","For each exercised warrant, company issues new warrant to purchase 150% of shares, exercisable at $6.00, 5-year term.","New warrants unregistered; company to file S-1 resale registration by July 25, 2024.","A.G.P. receives 6% fee of gross proceeds; net proceeds for clinical development and working capital.","Exhibit warns of potential Nasdaq delisting risk if compliance not regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236122,"accession_number":"0001558370-24-008803","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.03","5.03","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Soligenix to effect 1-for-16 reverse stock split effective June 5, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-16 ratio; effective 4:00 p.m. EST June 5, 2024.","Outstanding shares to reduce from 15,799,837 to ~987,490 (fractional shares rounded up).","Common stock begins trading on split-adjusted basis June 6, 2024 under ticker SNGX; new CUSIP 834223 604.","Stockholders approved reverse split at annual meeting; board set ratio at 1-for-16.","Proportionate adjustments to equity awards and warrants exercise prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236121,"accession_number":"0001558370-24-008642","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Soligenix adjourns 2024 annual meeting due to insufficient quorum; reconvenes May 30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only ~48% of outstanding shares were represented at May 23 meeting, below required majority.","Meeting adjourned to May 30, 2024 at 9:00 a.m. ET; will be held virtually.","Record date for voting remains April 10, 2024.","Company urges stockholders to vote via Internet, phone, or by contacting proxy solicitor Alliance Advisors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236120,"accession_number":"0001558370-24-008421","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix confirms compliance with Nasdaq $2.5M equity requirement after debt conversion and public offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Converted $154,840 of debt into equity on April 15, 2024.","Closed a $4.75 million public offering on April 22, 2024.","Company now believes it meets Nasdaq’s $2.5 million shareholders’ equity minimum.","These events were previously reported in the Q1 2024 10-Q filed May 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236119,"accession_number":"0001558370-24-005411","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soligenix prices $4.75M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.75M from unit offering: one share (or pre-funded warrant) and one common warrant per unit.","Units priced at $0.40; warrants exercisable at $0.40 per share with a five-year term.","Offering comprises up to 11.875M shares/common equivalents and 11.875M warrants; 8.6M pre-funded warrants included.","Net proceeds to fund R&D, commercialization activities, and general corporate and working capital purposes.","Closing expected on or about April 22, 2024; A.G.P./Alliance Global Partners acting as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236118,"accession_number":"0001558370-24-004663","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soligenix gets EMA agreement on confirmatory Phase 3 design for HyBryte in CTCL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA agreed on key design for FLASH2: double-blind, placebo-controlled, 18-week continuous treatment.","Study to enroll ~80 early-stage CTCL patients in US and Europe; enrollment targeted by end of 2024.","Primary endpoint: ≥50% reduction in mCAILS score at Week 18; top-line results expected H2 2026.","FLASH2 replicates first Phase 3 design but extends continuous treatment without breaks.","Discussions with FDA on US development path remain ongoing; company prioritizes EMA pathway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271286,"accession_number":"0001558370-23-019993","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Soligenix receives Nasdaq delisting notice; common stock may be suspended","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Soligenix on Dec 21, 2023, of failure to meet $1.00 minimum bid price rule.","Company ineligible for second 180-day cure period due to stockholders' equity of $4.22M (below $5M minimum).","Intends to request a hearing by Dec 28, 2023, to stay suspension pending panel decision.","Hearing expected within 45 days; company will present plan to regain compliance.","No immediate impact on listing; shares continue trading on Nasdaq under symbol SNGX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271285,"accession_number":"0001558370-23-019838","cik":812796,"company_name":"SOLIGENIX, INC.","ticker":"SNGX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Soligenix reconvenes annual meeting; elects all five director nominees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees were elected: Schaber, Lapointe, Parks, Rubin, Zeldis.","Advisory vote on executive compensation passed with 2,315,274 For vs. 707,529 Against.","Ratification of Cherry Bekaert LLP as auditor approved with 4,439,358 For.","Meeting required multiple adjournments from Sept 21, Oct 18, Nov 16 until quorum achieved.","Broker non-votes totaled 1,602,901 on director election and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12833286.989668617,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}